Live Breaking News & Updates on Syros Pharmaceuticals
Stay updated with breaking news from Syros pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Avidity Partners Management LP increased its position in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Free Report) by 5.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,673,538 shares of the company’s stock after purchasing an additional 92,396 shares during the […] ....
Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS – Get Free Report) crossed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $5.25 and traded as low as $4.99. Syros Pharmaceuticals shares last traded at $5.00, with a volume of 68,625 shares trading hands. Analyst Upgrades and Downgrades […] ....
HC Wainwright restated their buy rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) in a report issued on Wednesday, Benzinga reports. The firm currently has a $15.00 price target on the stock. HC Wainwright also issued estimates for Syros Pharmaceuticals’ Q2 2024 earnings at ($0.73) EPS, Q3 2024 earnings at ($0.74) EPS, Q4 […] ....
Syros Pharmaceuticals (NASDAQ:SYRS) Issues Quarterly Earnings Results, Beats Expectations By $0.10 EPS modernreaders.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernreaders.com Daily Mail and Mail on Sunday newspapers.
HC Wainwright reiterated their buy rating on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) in a report published on Wednesday morning, Benzinga reports. HC Wainwright currently has a $15.00 target price on the stock. A number of other research analysts have also recently issued reports on the stock. StockNews.com cut shares of Syros Pharmaceuticals […] ....